Literature DB >> 2454822

Cisplatin and intravenous continuous infusion of bleomycin in advanced and metastatic esophageal cancer.

E Marcuello1, E Alba, G Gómez de Segura, M Sánchez Parra, L de Andrés, A López Pousa, C Pallares, J R Germá, J J López López.   

Abstract

Thirty-four patients with locally advanced or metastatic esophageal cancer were treated with cisplatin 35 mg/m2/day x 3 days in bolus, plus bleomycin 15 mg/day x 3 days, as an 18 h infusion, every 21-28 days. Twenty-nine are evaluable for response. Objective response was seen in 15 (52%, 95% confidence limits 35-69%) patients. Toxicity was mild. Twelve patients with locoregional disease were treated with this combination followed by radiotherapy and three of them are alive without disease at 18, 22 and 36 months. This combination warrants further study in the setting of combined treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454822     DOI: 10.1016/0277-5379(88)90292-1

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  1 in total

1.  A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma.

Authors:  Shuji Hiramoto; Ken Kato; Hirokazu Shoji; Natsuko Okita; Atsuo Takashima; Yoshitaka Honma; Satoru Iwasa; Tetsuya Hamaguchi; Yasuhide Yamada; Yasuhiro Shimada; Narikazu Boku
Journal:  Int J Clin Oncol       Date:  2018-01-20       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.